Nvidia-backed Iambic Therapeutics raised $150 million in its initial public offering on October 14, 2026, selling 9.4 million shares at $16 to trade on the Nasdaq under symbol IAM. The AI drug discovery startup will fund its HER2-positive cancer drug IAM1363 toward a potential 2027 registrational trial, along with secondary pipelines targeting ovarian and breast cancers. Supported by partners like Takeda and AbbVie, Iambic becomes the 25th biotech IPO of 2026 in a surging market.
Iambic Therapeutics initial public offering
- ▪Iambic Therapeutics will begin trading publicly on the Nasdaq under the ticker symbol IAM on October 15, 2026
- ▪Iambic Therapeutics raised $150 million in an initial public offering on October 14, 2026, selling nearly 9.4 million shares at $16 each
Iambic Therapeutics clinical drug pipeline
- ▪Iambic Therapeutics is developing IAM217 for KIF18A-targeted ovarian and triple-negative breast cancers, alongside a third prospect targeting CDK2 and CDK4, with clinical testing for both potentially beginning in 2027
- ▪Iambic Therapeutics' lead clinical drug candidate IAM1363 is an oral HER2-positive solid tumor inhibitor that showed anti-tumor activity in Phase 1 trials and may enter registrational trials by 2027
Iambic Therapeutics AI technology platform
- ▪Iambic Therapeutics has partnered with drugmakers Takeda Pharmaceutical, AbbVie, Jazz Pharmaceuticals, and Revolution Medicines for its artificial intelligence technology platform
- ▪Iambic Therapeutics stated in its initial public offering filing that it uses artificial intelligence across drug research to identify potential medicines, optimize them, and predict clinical trial outcomes
Iambic Therapeutics Private investors
- ▪Prior to Iambic Therapeutics' IPO, the company raised $462 million in private funding since its 2019 launch from investors including Nexus, Catalio Capital Management, Abingworth, and Illumina Ventures
- ▪Nvidia is a financial backer of Iambic Therapeutics
Artificial intelligence drug discovery
- ▪Billions of dollars have been invested in young artificial intelligence drug discovery companies, while several large firms have begun integrating AI technology across their operations
- ▪Publicly traded artificial intelligence drug discovery companies have struggled following their initial public offerings amid industry concerns regarding overstated capabilities
Story comments
Loading comments…